HAHülya Albayrak

Hülya Albayrak

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hülya Albayrak has a total of 54 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Dermatological manifestations of hypoparathyroidism: a multicenter study

    by Hilal Kaya Erdoğan, Filiz Cebeci Kahraman, İsA An, Nurşad Çifçi, Hülya Albayrak, Mustafa Esen, Arzu Kılıç, Göknur Yorulmaz, Murat Cinel, Seda Erem Basmaz, et al.

  • Real‐World Predictors of Relapse‐Free Duration After Narrowband UVB in Pediatric Psoriasis: A Multicenter Study

    by Berna Solak, Burhan Engin, Zeynep Güngör, Ömer Faruk Tolun, Zafer Türkoğlu, Dilay Baştuğ, Harbiye Dilek Canat, Tubanur Çetinarslan, Aylin Türel Ermertcan, Selen Gezmen, et al.

    Background: Narrowband ultraviolet B (NB‐UVB) phototherapy is a well‐established, safe, and effective treatment for pediatric psoriasis; however, relapse after therapy remains a major challenge. Data regarding prognostic factors influencing remission durability in children are limited. Objectives: To evaluate treatment response, relapse patterns, and predictors of relapse‐free duration in pediatric psoriasis patients treated with NB‐UVB phototherapy, with a particular focus on concomitant topical corticosteroid and calcipotriol use, and clinical features such as nail involvement. Methods: This multicenter retrospective study included 114 pediatric psoriasis patients treated with NB‐UVB across six tertiary dermatology centers in Türkiye. Treatment response was defined as ≥ 75% improvement in the Psoriasis Area and Severity Index (PASI75). Relapse was defined as clinically significant recurrence requiring renewed NB‐UVB or systemic therapy within 6 months after treatment completion. Multivariable linear regression identified independent predictors of relapse‐free duration. Results: Of 114 patients (mean age 12.2 ± 3.6 years; 52.6% male), 65.8% achieved PASI75 and 42.1% PASI90. Responders received significantly higher cumulative doses and more sessions than nonresponders ( p < 0.001). Relapse occurred in 24.0% of responders within 6 months. In multivariate analysis, concomitant topical corticosteroid use independently predicted longer relapse‐free duration ( β = 0.578, p = 0.001), whereas nail involvement predicted shorter remission ( β = −0.520, p = 0.002). Topical calcipotriol and disease subtype were not significant predictors. NB‐UVB was well tolerated, with mild erythema and pruritus as the most frequent adverse events (16.7%). Conclusion: NB‐UVB phototherapy provides high efficacy and an acceptable safety profile in pediatric psoriasis. Concomitant topical corticosteroid use may prolong remission, while nail involvement identifies patients at higher relapse risk, supporting closer monitoring and individualized follow‐up and maintenance strategies.


  • Open Access

    Sex-Specific Autoimmune Comorbidity Patterns in Pemphigus Vulgaris and Bullous Pemphigoid: A Bicenter Retrospective Case–Control Study

    by Özge Zorlu, Serkan Yazici, Sidar İlik, Emel Bülbül Başkan, Hülya Albayrak, Sema Aytekin

    Background and Objectives: While pemphigus vulgaris (PV) and bullous pemphigoid (BP) have been linked to autoimmune comorbidities, the spectrum and specificity of these associations remain uncertain. We aimed to investigate the prevalence and patterns of autoimmune diseases (AIDs) in patients with PV and BP compared with age- and sex-matched controls. Materials and Methods: We conducted a bicenter, retrospective case–control study including 287 PV patients with 1148 matched controls and 284 BP patients with 1137 matched controls. Autoimmune comorbidities were identified through medical record review, and disease-specific as well as system-level associations between PV, BP, and AIDs were assessed. Results: Overall AID prevalence was lower in PV (9.4%) and BP (8.1%) than in controls (18% and 15%, respectively; p < 0.001 and p = 0.002). PV was associated with Graves’ disease (adjusted OR: 3.16, 95% CI: 1.24–8.06), especially in females. BP was associated with Hashimoto thyroiditis (adjusted OR: 2.51, 95% CI: 1.33–4.75), particularly in males. System-level analyses revealed that cutaneous and multisystem AIDs were less frequent in both PV and BP (p < 0.001 for each and p = 0.001 for each, respectively), whereas endocrine AIDs were more frequent in BP (p = 0.038). Thyroid antibody positivity did not differ significantly between patients and controls. Limitations include retrospective design, possible overrepresentation of cutaneous AIDs in dermatology-based controls, and lack of external validation. Conclusions: Our findings suggest that PV and BP may be associated with selective, sex- and phenotype-specific autoimmune comorbidity patterns rather than a generalized autoimmune burden. Further prospective studies are needed to confirm these exploratory associations and clarify their temporal relationships.


  • Predictors of response to omalizumab in chronic spontaneous urticaria: a retrospective cohort study

    by Özge Zorlu, Hülya Albayrak, Sema Aytekin

    Although omalizumab is a highly effective treatment against chronic spontaneous urticaria (CSU), the treatment duration for response varies among patients. Thus, determining easy-to-access predictive biomarkers of omalizumab response is essential. This study aimed to investigate the value of baseline hematological and inflammatory parameters and patient-specific features as predictive markers of response to standard-dose omalizumab. This single-center retrospective cohort study was conducted on 242 patients with CSU treated with omalizumab 300 mg every 4 weeks for at least 6 months between 2014 and 2025. The demographics, clinical features, treatment responses, and baseline laboratory tests were assessed. Response to omalizumab was evaluated based on the weekly Urticaria Activity Score (UAS7). Patients were categorized as early responder (ER, within 3 months), late responder (LR, after 3 months), and nonresponder (NR). Of patients, 180 (74.4%) were classified as ER, 28 (11.6%) as LR, and 34 (14%) as NR. ERs had higher white blood cell (WBC) and lymphocyte counts (p = 0.047 and p = 0.005, respectively) and lower mean platelet volume (MPV)/lymphocyte ratio (MPVLR) (p = 0.008). LRs had higher mean corpuscular hemoglobin concentration (MCHC) and platelet/lymphocyte ratio (PLR) (p = 0.023 and p = 0.014, respectively) and lower MPV levels (p = 0.043). The platelet distribution width (PDW) was higher in the NRs (p = 0.011). Red cell distribution width-coefficient of variation (RDW-CV) [odds ratio (OR): 0.793, 95% confidence interval (CI): 0.641-0.980, p = 0.032], WBC count (OR: 1.418, 95% CI: 1.093-1.840, p = 0.009), and PDW (OR: 0.813, 95% CI: 0.693-0.954, p = 0.011) were found to be the independent predictors of responders. The lymphocyte count (OR: 1.713, 95% CI: 1.122-2.613, p = 0.013) and MPVLR (OR: 0.427, 95% CI: 0.218-0.837, p = 0.013) were independent predictors of ER, whereas MCHC (OR: 2.368, 95% CI: 1.522-3.686, p < 0.001) and PLR (OR: 1.010, 95% CI: 1.003-1.017, p = 0.003) were independent predictors of LR. The receiver operating characteristic curve analysis results showed that the predictive strengths of RDW-CV, WBC count, PDW, lymphocyte count, MPVLR, MCHC, and PLR were low (the area under the curve values 0.634, 0.620, 0.672, 0.656, 0.621, 0.649, and 0.624, respectively; all p < 0.05), suggesting the limited use of these parameters in clinical practice. The limitations of this study included its single-center, retrospective design, lack of external validation, and reliance solely on UAS7 for assessing disease activity. WBC and lymphocyte counts, RDW-CV, PDW, MPVLR, MCHC, and PLR can be considered when appraising the omalizumab response. However, given their limited predictive strength, these parameters alone may not accurately predict the efficacy of omalizumab.

  • Demographics, Clinical and Laboratory Features of Childhood Vitiligo: A Retrospective Cross-sectional Analysis of 179 Patients

    by Özge Zorlu, Büşra Demirel, Hülya Albayrak, Sema Aytekin

    Vitiligo is an acquired pigmentation disorder. Childhood vitiligo can differ from adult-onset vitiligo in several aspects. We aimed to evaluate demographics, clinical features of vitiligo in children, and laboratory results. A retrospective, cross-sectional study was conducted on < 18-year-old pediatric patients with vitiligo. Demographics, clinical features, and laboratory test results performed at the time of diagnosis were retrieved from medical records. Vitiligo was classified as non-segmental (NSV), segmental (SV), and unclassified vitiligo. A total of 179 patients were included. The female/male ratio was 1.2/1. The most common form was NSV (87.7%), followed by SV (7.3%). Among NSV, generalized vitiligo was the most common subtype (42.5%), followed by localized (32.4%) and acrofacial (8.9%) vitiligo. Vitiligo began ≤ 12 years of age in 156 (88.6%) patients. NSV and SV were not significantly different in sex, age of disease onset, disease duration, halo nevi, or Koebner phenomenon. Leukotrichia was more common in SV (84.6%) than NSV (7.6%) (P < 0.001). Face (67.6%) was the most frequently involved body site. Neutrophil percentage, mean platelet volume (MPV), MPV/platelet ratio, MPV/lymphocyte ratio, neutrophil/lymphocyte ratio (NLR), derived NLR, and systemic inflammatory response index were significantly lower in patients with early-onset (≤ 12 years) vitiligo (P < 0.05), possibly indicating the differences in inflammatory response between young children and adolescents. It was noteworthy that eosinophil counts, eosinophil/monocyte ratio, and eosinophil/neutrophil ratio were significantly lower in female patients (P < 0.05), which might reflect the effect of sex hormones on eosinophils. Further studies are warranted to extend our results.

  • Impact of oral isotretinoin on the inflammatory markers: can lymphocyte/HDL-C and platelet/HDL-C ratios be new indicators of inflammation in acne vulgaris patients?

    by Özge Zorlu, Hülya Albayrak, Sema Aytekin

    The effect of isotretinoin on inflammatory markers has been reported with conflicting results. No studies have been reported on the relationship between isotretinoin and lymphocyte/high-density lipoprotein cholesterol [HDL-C] ratio (LHR), neutrophil/HDL-C ratio (NHR), or platelet/HDL-C ratio (PHR) in acne patients. We aimed to investigate how isotretinoin affects the inflammatory markers, including LHR, NHR, and PHR, in acne vulgaris patients. A total of 361 patients with moderate-to-severe acne vulgaris who received systemic isotretinoin for at least six months were included. Complete blood count and biochemical analyses, including monocyte/HDL-C ratio (MHR), NHR, LHR, PHR, neutrophil/lymphocyte ratio (NLR), monocyte/lymphocyte ratio (MLR), platelet/lymphocyte ratio (PLR), the aggregate index of systemic inflammation (AISI), systemic immune-inflammation index (SII), and systemic inflammation response index (SIRI), obtained at the treatment onset and the end of the first, third, and sixth months of treatment were investigated. There was no significant difference in MHR and NHR levels between repeated measures. A significant increasing trend was seen in LHR and PHR (P = 0.001 and P = 0.011, respectively). HDL-C levels gradually and significantly declined during the six months (P < 0.001). Serum NLR, derived NLR, SII, SIRI, MLR, and AISI showed a significant decrease in line with clinical improvement in acne during the six months of therapy (P < 0.05). Declining levels of NLR, MLR, SII, SIRI, and AISI may indicate the anti-inflammatory effects of isotretinoin on the pilosebaceous unit, whereas increasing levels of LHR and PHR may show systemic inflammatory activity of isotretinoin.


  • Open Access

    Neutrophil-to-Lymphocyte Ratio, Neutrophil-to-Monocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune-Inflammation Index in Psoriasis Patients: Response to Treatment with Biological Drugs

    by Hulya Albayrak

    Background: Psoriasis is a chronic immune-mediated skin disease in which systemic inflammation plays an important role in its pathogenesis. In recent years, the neutrophil-to-lymphocyte ratio (NLR), neutrophil-to-monocyte ratio (NMR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII) were shown to be important indicators of inflammation. This study aimed to investigate the NLR, NMR, PLR, and SII levels in psoriasis patients treated with biological agents. Method: Clinical and biochemical data of 209 patients who received systemic therapy for psoriasis were obtained by retrospectively reviewing their medical records. The NLR, NMR, PLR, and SII values were calculated from the hemogram values of the patients. Results: In the third month of follow-up, the mean CRP, NLR, NMR, PLR, and SII values were significantly decreased compared with the baseline values. The SII values showed strong positive correlations with the NLR, NMR, and PLR. Adalimumab, etanercept, and infliximab, which are TNF-α blockers, were observed to be more effective on the PLR and NLR, and especially the NMR. Conclusions: The NLR, NMR, PLR, and SII, which are data derived from routine blood tests, can be used in the monitoring of the treatment of psoriasis, especially with TNF-α blockers.


  • Open Access

    Neutrophil-to-Lymphocyte Ratio, Neutrophil-to-Monocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune-Inflammation Index in Psoriasis Patients: Response To Treatment With Biological Drugs

    by Hulya Albayrak

    Background: Psoriasis is a chronic immune-mediated skin disease in which systemic inflammation plays an important role in the pathogenesis. In recent years, neutrophil-to-lymphocyte ratio (NLR), neutrophil-to-monocyte ratio (NMR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII) have been shown to be important indicators of inflammation. In this study, our aim is to investigate NLR, NMR, PLR, and SII levels in psoriasis patients treated with biologic agents. Method: Clinical and biochemical data of 209 patients who received systemic therapy for psoriasis were obtained by retrospectively reviewing their medical records. NLR, NMR, PLR, and SII values were calculated from the hemogram values of the patients. Results: In the third month of follow-up, the mean CRP, NLR, NMR, PLR, and SII values were significantly decreased compared to the baseline values. SII values showed strong positive correlations with NLR, NMR and PLR. Adalimumab, etanercept, and infliximab, which are TNF-α blockers, were observed to be more effective on PLR and NLR and especially NMR. Conclusion: NLR, NMR, PLR, and SII, which are data obtained from routine blood tests, can be used in the monitoring of treatment of psoriasis, especially with TNF- α blockers.


  • Open Access

    Relationship between vitamin D in obstructive sleep apnea syndrome and psoriasis patients

    by Hülya Albayrak, Nevin Fazlıoğlu, Bahadır Batar, Mehmet Emin Yanık, Mustafa Oran, Nejat Altıntaş

    Introduction Although psoriasis and obstructive sleep apnea syndrome (OSAS) are associated with systemic inflammation, studies on their potential bilateral relationship are not sufficient. Aim: To investigate vitamin D levels and receptor gene polymorphisms in patients with OSAS and...